1. Volume 15, Issue 4, Pages 464-473 (April 2014)
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long- term results from the MRC RT01 randomised controlled trial 
Prof David P Dearnaley, FRCR, Gordana Jovic, PhD, Isabel Syndikus, FRCR, Vincent Khoo, FRCR, Richard A Cowan, FRCR, John D Graham, FRCR, Edwin G Aird, PhD, David Bottomley, FRCR, Robert A Huddart, FRCR, Chakiath C Jose, FRANZCR, John H L Matthews, FRANZCR, Jeremy L Millar, FRANZCR, Claire Murphy, BSc, J Martin Russell, FRCR, Christopher D Scrase, FRCR, Prof Mahesh K B Parmar, DPhil, Matthew R Sydes, MSc 
The Lancet Oncology 
Volume 15, Issue 4, Pages (April 2014)
DOI: /S (14)
Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions

2. Figure 1
Trial profile
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions

3. Figure 2
Primary analysis of overall survival and biochemical progression-free survival
(A) Overall survival, predicted from Kaplan-Meier function and flexible parametric model. (B) Absolute difference in overall survival, from flexible parametric model. (C) Biochemical progression-free survival, predicted by Kaplan-Meier function and flexible parametric model. (D) Absolute difference in biochemical progression-free survival, from flexible parametric model.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions

4. Figure 3
Subgroup analyses of overall survival and biochemical progression-free survival
(A) Overall survival and risk of seminal vesicle involvement. (B) Overall survival and National Comprehensive Cancer Network risk group. (C) Biochemical progression-free survival and risk of seminal vesicle involvement. (D) Biochemical progression-free survival and National Comprehensive Cancer Network risk group. HR=hazard ratio.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions

5. Figure 4 Additional outcome measures
(A) Progression-free survival, Kaplan-Meier plot. (B) Initiation of ADT, Kaplan-Meier plot. (C) Metastases-free survival, Kaplan-Meier plot. (D) Cumulative incidence of PC deaths and non-PC deaths. ADT=androgen deprivation therapy. PC=prostate cancer.
The Lancet Oncology  , DOI: ( /S (14) )
Copyright © 2014 Dearnaley et al. Open Access article distributed under the terms of CC BY Terms and Conditions